Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT A HAUSER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1558384743
CMS profile
342421
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$324,868.27

271 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Amneal Pharmaceuticals LLC $99,474.02 46
Acorda Therapeutics, Inc $64,502.32 37
Neurocrine Biosciences, Inc. $37,888.98 59
Kyowa Kirin, Inc. $37,093.33 28
US WorldMeds, LLC $23,981.48 50
ACADIA Pharmaceuticals Inc $19,152.89 18
H. Lundbeck A S $17,225.22 4
Adamas Pharmaceuticals, Inc. $10,700.00 12
Mitsubishi Tanabe Pharma America, Inc. $7,231.87 2
Teva Pharmaceuticals USA, Inc. $2,373.95 8
JAZZ PHARMACEUTICALS INC. $2,100.00 2
Lundbeck LLC $1,618.84 2
APO-PHARMA INC. $1,500.00 1
Allergan Inc. $13.69 1
AbbVie, Inc. $11.68 1

Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT A HAUSER

NPI 1558384743 · CMS profile ID 342421

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558384743?year=2019&recipient=provider&page=6#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT A HAUSER, NPI 1558384743, CMS profile ID 342421. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558384743?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ROBERT A HAUSER, NPI 1558384743, CMS profile ID 342421. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558384743?year=2019&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ROBERT A HAUSER, NPI 1558384743, CMS profile ID 342421, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–271 of 271 matching records. This page contains 21 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1558384743?year=2019&recipient=provider&page=6#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

271 matching records · $324,868.27 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 271 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 251–271 of 271.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Neurocrine Biosciences, Inc. $54.9602/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693134099 CMS
Neurocrine Biosciences, Inc. $59.4202/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693134101 CMS
Neurocrine Biosciences, Inc. $4,000.0002/16/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693134103 CMS
Neurocrine Biosciences, Inc. $380.6002/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693134073 CMS
Neurocrine Biosciences, Inc. $29.1702/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693134075 CMS
Neurocrine Biosciences, Inc. $17.6602/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693134079 CMS
Neurocrine Biosciences, Inc. $125.0002/15/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693134081 CMS
Acorda Therapeutics, Inc $12.6601/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633494801 CMS
Acorda Therapeutics, Inc $7.6501/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633494799 CMS
JAZZ PHARMACEUTICALS INC. $1,500.0001/30/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684155461 CMS
ACADIA Pharmaceuticals Inc $63.6001/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005343 CMS
ACADIA Pharmaceuticals Inc $11.5701/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005345 CMS
ACADIA Pharmaceuticals Inc $93.3701/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005347 CMS
ACADIA Pharmaceuticals Inc $11.0101/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005349 CMS
ACADIA Pharmaceuticals Inc $9,500.0001/24/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005331 CMS
ACADIA Pharmaceuticals Inc $93.3701/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005333 CMS
ACADIA Pharmaceuticals Inc $386.1001/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005335 CMS
ACADIA Pharmaceuticals Inc $58.3401/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005337 CMS
ACADIA Pharmaceuticals Inc $29.7701/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005339 CMS
ACADIA Pharmaceuticals Inc $653.1401/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700005341 CMS
Acorda Therapeutics, Inc $500.0001/15/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633494797 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $324,868.27 271
PY2020 $212,735.35 131
PY2021 $161,405.83 77
PY2022 $169,724.77 170
PY2023 $238,605.68 233
PY2024 $213,160.85 148
PY2025 $271,486.92 299

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,002.10 2
PY2025 Principal investigator $1,000,583.03 142
PY2024 Recipient $1,416.14 6
PY2024 Principal investigator $1,042,300.41 59
PY2023 Principal investigator $922,088.00 59
PY2022 Principal investigator $808,666.23 62
PY2021 Recipient $374.16 1
PY2021 Principal investigator $679,214.02 62
PY2020 Recipient $336.64 2
PY2020 Principal investigator $533,838.21 35
PY2019 Principal investigator $1,080,594.13 79

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

144 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,656.72 12/31/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
An Open-Label Extension of Studies M15-736 and M20-339 to Evaluate the Safety and Tolerability of 24-Hour Daily Exposure of ABBV-951 in Subjects With Advanced Parkinson s Disease No dispute reported 06/30/2026 1202534217
Principal investigator 1 Roche TCRC, Inc. $1,931.00 12/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669954
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,924.45 12/19/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046944
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $172.80 12/19/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046946
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $135.00 12/19/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046948
Principal investigator 1 Roche TCRC, Inc. $635.50 12/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669958
Principal investigator 1 Roche TCRC, Inc. $3,483.22 12/18/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669961
Principal investigator 1 ABBVIE INC. $100.00 12/11/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Open-label Trial in Parkinsons Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202530118
Recipient Amneal Pharmaceuticals LLC $3,627.10 12/11/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530670
Recipient Amneal Pharmaceuticals LLC $375.00 12/11/2025 Covered Recipient Physician IPX203-401-23 No dispute reported 06/30/2026 1220530675
Principal investigator 1 ABBVIE INC. $2,160.00 12/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202527910
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,036.80 12/04/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046934
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,685.15 12/04/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046936
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,156.00 12/04/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046938
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $114.75 12/04/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046940
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $515.70 12/04/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046942
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,424.66 11/26/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046932
Principal investigator 1 ABBVIE INC. $250.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORI
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202524591
Principal investigator 1 ABBVIE INC. $250.00 11/19/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202524626
Principal investigator 1 ABBVIE INC. $1,000.00 11/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202524395
Principal investigator 1 Roche TCRC, Inc. $9,240.30 11/13/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669949
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,087.16 11/06/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046930
Principal investigator 1 ABBVIE INC. $2,160.00 11/05/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202521561
Principal investigator 1 Ipsen Innovation $2,000.00 10/31/2025 Non-covered Recipient Entity
University Of South Florida Health
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184290836
Principal investigator 1 Ipsen Innovation $13,865.00 10/31/2025 Non-covered Recipient Entity
University Of South Florida Health
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184290838
Principal investigator 1 Ipsen Innovation $2,500.00 10/31/2025 Non-covered Recipient Entity
University Of South Florida Health
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184290842
Principal investigator 1 Ipsen Innovation $2,750.00 10/31/2025 Non-covered Recipient Entity
University Of South Florida Health
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184290844
Principal investigator 1 Genentech, Inc. $2,374.00 10/29/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211670700
Principal investigator 1 Ipsen Innovation $3,300.00 10/29/2025 Non-covered Recipient Entity
University Of South Florida Health
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184290840
Principal investigator 1 Genentech, Inc. $62,160.00 10/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211670694
Principal investigator 1 Roche TCRC, Inc. $589.50 10/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669946
Principal investigator 1 ABBVIE INC. $625.00 10/22/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
a glogal real world evidence study on the long term effect of abbv-951 No dispute reported 06/30/2026 1202517707
Principal investigator 1 ABBVIE INC. $625.00 10/22/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202518083
Principal investigator 1 ABBVIE INC. $928.80 10/16/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202517177
Principal investigator 1 Roche TCRC, Inc. $38,167.20 10/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669938
Principal investigator 1 ABBVIE INC. $4,252.50 10/09/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202514593
Principal investigator 1 Roche TCRC, Inc. $6,934.50 10/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669922
Principal investigator 1 Roche TCRC, Inc. $1,905.40 10/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669927
Principal investigator 1 Roche TCRC, Inc. $1,511.38 10/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669933
Principal investigator 1 Roche TCRC, Inc. $1,500.00 10/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669942
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $23,898.38 10/09/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046926
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $200.00 10/09/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046928
Principal investigator 1 Ipsen Innovation $43.50 09/26/2025 Non-covered Recipient Entity
Usf Health Byrd Alzheimers Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288468
Principal investigator 1 Ipsen Innovation $3,989.94 09/23/2025 Non-covered Recipient Entity
Usf Health Byrd Alzheimers Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288472
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,268.70 09/23/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046924
Principal investigator 1 Roche TCRC, Inc. $4,218.00 09/11/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669911
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,402.69 09/11/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046922
Principal investigator 1 ABBVIE INC. $6,952.50 09/04/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202509954
Principal investigator 1 Roche TCRC, Inc. $775.68 08/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669889
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $909.23 08/26/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046920
Principal investigator 1 ABBVIE INC. $250.00 08/21/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202505529
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,532.35 08/21/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046918
Principal investigator 1 Roche TCRC, Inc. $2,188.70 08/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669885
Principal investigator 1 Roche TCRC, Inc. $3,835.80 08/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669905
Principal investigator 1 Roche TCRC, Inc. $1,486.74 08/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669916
Principal investigator 1 Roche TCRC, Inc. $1,271.37 08/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669919
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,779.08 08/14/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046916
Principal investigator 1 ABBVIE INC. $333.33 08/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202504287
Principal investigator 1 Ipsen Innovation $3,952.37 08/08/2025 Non-covered Recipient Entity
Usf Health Byrd Alzheimers Institute
A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants No dispute reported 06/30/2026 1184288474
Principal investigator 1 ABBVIE INC. $3,073.95 08/05/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202502144
Principal investigator 1 Roche TCRC, Inc. $491.75 08/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669882
Principal investigator 1 Roche TCRC, Inc. $3,000.00 08/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669893
Principal investigator 1 Roche TCRC, Inc. $703.00 08/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669897
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,277.15 07/31/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046914
Principal investigator 1 ABBVIE INC. $1,285.20 07/17/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202498564
Principal investigator 1 ABBVIE INC. $21,000.00 07/17/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202498570
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,268.70 07/17/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046912
Principal investigator 1 ABBVIE INC. $250.00 07/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202497076
Principal investigator 1 ABBVIE INC. $4,252.50 07/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202497078
Principal investigator 1 ABBVIE INC. $8,200.00 07/08/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202497080
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $16,686.01 07/03/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046910
Principal investigator 1 ABBVIE INC. $2,146.50 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202494377
Principal investigator 1 ABBVIE INC. $11,815.00 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202494501
Principal investigator 1 ABBVIE INC. $4,252.50 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202494503
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,500.00 06/24/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046900
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $172.80 06/24/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046902
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $737.10 06/24/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046904
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $114.75 06/24/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046906
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,132.00 06/24/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046908
Principal investigator 1 Roche TCRC, Inc. $72,204.30 06/19/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669765
Principal investigator 1 Roche TCRC, Inc. $408.00 06/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669783
Principal investigator 1 Roche TCRC, Inc. $408.00 06/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669807
Principal investigator 1 Roche TCRC, Inc. $3,092.85 06/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669824
Principal investigator 1 Roche TCRC, Inc. $476.00 06/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669829
Principal investigator 1 Roche TCRC, Inc. $408.00 06/05/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669859
Principal investigator 1 ABBVIE INC. $9,652.50 06/03/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202488777
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $889.00 06/01/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046898
Principal investigator 1 Roche TCRC, Inc. $1,186.69 05/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669865
Principal investigator 1 Roche TCRC, Inc. $282.96 05/28/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669868
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $500.00 05/27/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046896
Principal investigator 1 Roche TCRC, Inc. $23,992.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669745
Principal investigator 1 Roche TCRC, Inc. $649.51 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669750
Principal investigator 1 Roche TCRC, Inc. $288.60 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669756
Principal investigator 1 Roche TCRC, Inc. $521.50 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669773
Principal investigator 1 Roche TCRC, Inc. $818.86 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669779
Principal investigator 1 Roche TCRC, Inc. $476.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669787
Principal investigator 1 Roche TCRC, Inc. $3,241.63 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669792
Principal investigator 1 Roche TCRC, Inc. $263.96 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669797
Principal investigator 1 Roche TCRC, Inc. $2,184.32 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669802
Principal investigator 1 Roche TCRC, Inc. $476.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669810
Principal investigator 1 Roche TCRC, Inc. $340.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669815
Principal investigator 1 Roche TCRC, Inc. $1,200.71 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669818
Principal investigator 1 Roche TCRC, Inc. $696.75 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669821
Principal investigator 1 Roche TCRC, Inc. $589.50 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669842
Principal investigator 1 Roche TCRC, Inc. $408.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669846
Principal investigator 1 Roche TCRC, Inc. $1,151.88 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669852
Principal investigator 1 Roche TCRC, Inc. $681.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669855
Principal investigator 1 Roche TCRC, Inc. $1,472.10 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669863
Principal investigator 1 Roche TCRC, Inc. $521.50 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669872
Principal investigator 1 Roche TCRC, Inc. $612.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669878
Principal investigator 1 Genentech, Inc. $253,280.00 05/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211670641
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,750.00 05/08/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046890
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,650.00 05/08/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046892
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $12,500.00 05/08/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046894
Principal investigator 1 ABBVIE INC. $7,526.25 05/07/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202483583
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,532.35 05/02/2025 Non-covered Recipient Entity
The University of South Florida
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244046888
Principal investigator 1 Roche TCRC, Inc. $136.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669759
Principal investigator 1 Roche TCRC, Inc. $708.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669769
Principal investigator 1 Roche TCRC, Inc. $544.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669776
Principal investigator 1 Roche TCRC, Inc. $619.51 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669835
Principal investigator 1 Roche TCRC, Inc. $1,043.00 04/24/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669838
Principal investigator 1 Genentech, Inc. $4,373.60 04/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211670649
Principal investigator 1 ABBVIE INC. $6,565.50 04/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202474483
Principal investigator 1 ABBVIE INC. $1,000.00 04/04/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202474486
Principal investigator 1 ABBVIE INC. $16,700.00 04/03/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson s Disease No dispute reported 06/30/2026 1202470786
Principal investigator 1 ABBVIE INC. $50.00 03/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson s Disease With Motor Fluctuations (TEMPO-3) No dispute reported 06/30/2026 1202465425
Principal investigator 1 Roche TCRC, Inc. $864.73 03/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669735
Principal investigator 1 ABBVIE INC. $3,015.90 03/06/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202458054
Principal investigator 1 Roche TCRC, Inc. $655.51 03/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669725
Principal investigator 1 Roche TCRC, Inc. $702.75 03/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669728
Principal investigator 1 Roche TCRC, Inc. $871.51 03/06/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669742
Principal investigator 1 ABBVIE INC. $1,300.00 02/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202453422
Principal investigator 1 ABBVIE INC. $4,750.00 02/20/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202453436
Principal investigator 1 Genentech, Inc. $3,196.80 02/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211670623
Principal investigator 1 ABBVIE INC. $150.00 02/13/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202451853
Principal investigator 1 Sage Therapeutics, LLC $1,458.33 02/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFECTS OF SAGE-718 IN PARKINSON'S DISEASE COGNITIVE IMPAIRMENT No dispute reported 06/30/2026 1206580851
Principal investigator 1 Roche TCRC, Inc. $75,439.80 01/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669732
Principal investigator 1 Roche TCRC, Inc. $645.09 01/16/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211669738
Principal investigator 1 Genentech, Inc. $999.00 01/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES UNIVERSITY OF SOUTH FLORIDA
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211670633
Principal investigator 1 UCB SA $57,541.82 01/13/2025 Non-covered Recipient Entity
UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246658330
Principal investigator 1 ABBVIE INC. $1,285.20 01/09/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202437760
Principal investigator 1 UCB SA $18,890.75 01/09/2025 Non-covered Recipient Entity
UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE No dispute reported 06/30/2026 1246656953
Principal investigator 1 ABBVIE INC. $550.00 01/03/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202436500
Principal investigator 1 ABBVIE INC. $438.75 01/02/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202435693